TWI781912B - 有效於治療肝毒性及脂肪肝疾病的化合物及其用途 - Google Patents

有效於治療肝毒性及脂肪肝疾病的化合物及其用途 Download PDF

Info

Publication number
TWI781912B
TWI781912B TW105131118A TW105131118A TWI781912B TW I781912 B TWI781912 B TW I781912B TW 105131118 A TW105131118 A TW 105131118A TW 105131118 A TW105131118 A TW 105131118A TW I781912 B TWI781912 B TW I781912B
Authority
TW
Taiwan
Prior art keywords
group
liver
combination
mannitol
pharmaceutically acceptable
Prior art date
Application number
TW105131118A
Other languages
English (en)
Chinese (zh)
Other versions
TW201722897A (zh
Inventor
胡幼圃
石東原
熊正輝
何欣恬
Original Assignee
欣耀生醫股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/078039 external-priority patent/WO2017084234A1/zh
Application filed by 欣耀生醫股份有限公司 filed Critical 欣耀生醫股份有限公司
Publication of TW201722897A publication Critical patent/TW201722897A/zh
Application granted granted Critical
Publication of TWI781912B publication Critical patent/TWI781912B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/21—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen
    • C07C51/215—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen of saturated hydrocarbyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/42—Glutaric acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TW105131118A 2015-09-24 2016-09-26 有效於治療肝毒性及脂肪肝疾病的化合物及其用途 TWI781912B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562222959P 2015-09-24 2015-09-24
US62/222,959 2015-09-24
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19
PCT/CN2016/078039 WO2017084234A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物
WOPCT/CN2016/078039 2016-03-31

Publications (2)

Publication Number Publication Date
TW201722897A TW201722897A (zh) 2017-07-01
TWI781912B true TWI781912B (zh) 2022-11-01

Family

ID=60047309

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105131118A TWI781912B (zh) 2015-09-24 2016-09-26 有效於治療肝毒性及脂肪肝疾病的化合物及其用途

Country Status (20)

Country Link
US (4) US10456371B2 (https=)
EP (3) EP3991724B1 (https=)
JP (2) JP2018537517A (https=)
KR (2) KR20240042148A (https=)
CN (3) CN107614475A (https=)
AU (3) AU2016327930B2 (https=)
BR (1) BR112018005905B1 (https=)
CA (2) CA3232521A1 (https=)
EA (1) EA201890810A1 (https=)
ES (1) ES3044383T3 (https=)
HK (1) HK1244266A1 (https=)
HR (1) HRP20250899T1 (https=)
HU (1) HUE072982T2 (https=)
MX (2) MX395231B (https=)
MY (1) MY190647A (https=)
PH (1) PH12018500659A1 (https=)
SG (1) SG10202002573RA (https=)
TW (1) TWI781912B (https=)
WO (1) WO2017050298A1 (https=)
ZA (1) ZA201802373B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3069733T3 (pl) * 2013-11-13 2023-02-13 National Defense Education And Research Foundation Nowa kompozycja związku stanowiącego acetaminofen niepowodująca w wątrobie działań niepożądanych
WO2017084234A1 (zh) * 2015-11-19 2017-05-26 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
EA201890810A1 (ru) 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN111867572A (zh) * 2018-02-14 2020-10-30 欣耀生医股份有限公司 用于预防、减少或消除由对乙酰氨基酚(apap)引起的毒性的方法和组合物
CN110538187A (zh) * 2018-05-28 2019-12-06 北京大学 Cpt1激活剂
KR102136326B1 (ko) * 2018-09-06 2020-07-22 서울대학교산학협력단 가시박으로부터 분리한 플라보노이드 유도체를 유효성분으로 포함하는 간 질환 예방 또는 치료용 조성물
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
TWI858005B (zh) * 2019-01-21 2024-10-11 新加坡商新加坡保健服務私人有限公司 肝毒性之治療
CN110269855A (zh) * 2019-07-19 2019-09-24 辽宁大学 黄酮类小分子化合物在制备抑制胰脂肪酶活性药物中的应用
US12383191B1 (en) * 2020-05-04 2025-08-12 PathAI, Inc. Systems and methods for assessing liver pathology
CN113999272A (zh) * 2021-10-29 2022-02-01 广西医科大学 香蜂草苷的制备方法及其应用
CN113875982A (zh) * 2021-11-19 2022-01-04 武汉森澜生物科技有限公司 一种含二氢杨梅素的抗衰组合物及其应用
CN117482082A (zh) * 2023-11-27 2024-02-02 西北大学 金松双黄酮在制备抗慢性肾损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201515647A (zh) 2013-10-25 2015-05-01 Nat Defense Education And Res Foundation 無肝副作用之對乙醯胺基酚（Ａｃｅｔａｍｉｎｏｐｈｅｎ，ＡＰＡＰ）新複方組合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661519A (en) * 1983-04-12 1987-04-28 Pola Chemical Industries Inc. Method for dermatological application
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JP3916685B2 (ja) * 1996-02-29 2007-05-16 第一製薬株式会社 ガラクトース誘導体
JP4677550B2 (ja) * 2002-08-14 2011-04-27 独立行政法人産業技術総合研究所 環状エステル化合物
TWI287990B (en) * 2004-01-08 2007-10-11 Nat Defense Medical Ct Inhibitors and enhancers of uridine diphosphate-glucuronosyl transferase 2B (UGT2B)
WO2006010083A2 (en) * 2004-07-08 2006-01-26 Molecular Therapeutics, Inc. Biodegradable nanoparticles
CN1939929A (zh) * 2005-09-29 2007-04-04 云南白药集团股份有限公司 一种偏诺皂苷类化合物酸式盐及制备方法
DE112011105169B4 (de) * 2011-04-20 2021-11-04 National Defense Education And Research Foundation Neue pharmazeutische orale Zusammensetzung mit geringen Nebenwirkungen enthaltend anti-Tuberkulose Arzneimittel
KR20150084897A (ko) * 2012-11-12 2015-07-22 세게티스, 인코포레이티드. 가교성 폴리케탈 에스터, 그의 제조 방법 및 용도
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
JP6194412B2 (ja) * 2013-04-29 2017-09-06 ハーシャ チグルパティ アルコール飲料の毒性低減
CN104623670A (zh) * 2013-11-06 2015-05-20 高松 一种含西红花素的组合物及其应用
PL3069733T3 (pl) * 2013-11-13 2023-02-13 National Defense Education And Research Foundation Nowa kompozycja związku stanowiącego acetaminofen niepowodująca w wątrobie działań niepożądanych
CN104292289B (zh) * 2014-07-10 2017-12-29 程怡 半乳糖配体及其在肝靶向脂质体中的应用
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
WO2017084234A1 (zh) * 2015-11-19 2017-05-26 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201515647A (zh) 2013-10-25 2015-05-01 Nat Defense Education And Res Foundation 無肝副作用之對乙醯胺基酚（Ａｃｅｔａｍｉｎｏｐｈｅｎ，ＡＰＡＰ）新複方組合

Also Published As

Publication number Publication date
JP2018537517A (ja) 2018-12-20
BR112018005905A2 (pt) 2018-10-16
PH12018500659A1 (en) 2018-10-01
US11285123B2 (en) 2022-03-29
KR20180058795A (ko) 2018-06-01
SG10202002573RA (en) 2020-05-28
AU2016327930B2 (en) 2021-04-15
WO2017050298A1 (en) 2017-03-30
EP3353144A1 (en) 2018-08-01
EP3991724A3 (en) 2022-07-27
MX2022007816A (es) 2022-08-02
AU2024200963A1 (en) 2024-03-07
AU2016327930A1 (en) 2018-05-10
MX2018003700A (es) 2018-08-01
TW201722897A (zh) 2017-07-01
MY190647A (en) 2022-04-30
EP4609911A3 (en) 2025-11-19
EP3991724A2 (en) 2022-05-04
US20180256526A1 (en) 2018-09-13
EP3353144A4 (en) 2019-06-05
CN120349362A (zh) 2025-07-22
MX395231B (es) 2025-03-25
BR112018005905B1 (pt) 2023-03-21
EP3991724B1 (en) 2025-07-16
KR102891137B1 (ko) 2025-11-25
HUE072982T2 (hu) 2025-12-28
US12083088B2 (en) 2024-09-10
JP2022009680A (ja) 2022-01-14
EA201890810A1 (ru) 2018-11-30
CN120398980A (zh) 2025-08-01
EP4609911A2 (en) 2025-09-03
CN107614475A (zh) 2018-01-19
AU2021205040A1 (en) 2021-08-12
KR20240042148A (ko) 2024-04-01
AU2024200963B2 (en) 2026-02-12
US10456371B2 (en) 2019-10-29
US20240335404A1 (en) 2024-10-10
AU2021205040B2 (en) 2023-11-16
HK1244266A1 (zh) 2018-08-03
US20200009097A1 (en) 2020-01-09
CA3232521A1 (en) 2017-03-30
US20220265587A1 (en) 2022-08-25
ES3044383T3 (en) 2025-11-26
HRP20250899T1 (hr) 2025-11-07
JP7261850B2 (ja) 2023-04-20
EP3991724C0 (en) 2025-07-16
CA2999368A1 (en) 2017-03-30
ZA201802373B (en) 2019-04-24

Similar Documents

Publication Publication Date Title
TWI781912B (zh) 有效於治療肝毒性及脂肪肝疾病的化合物及其用途
US10765660B2 (en) Agent containing flavonoid derivatives for treating cancer and inflammation
RU2431634C2 (ru) Соединения флавоноидов и их применение
Lee et al. Determination of flavonoids from Cirsium japonicum var. maackii and their inhibitory activities against aldose reductase
US20140120181A1 (en) Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent
HK40128564A (zh) 有效於治疗肝毒性及脂肪肝疾病的化合物及其用途
HK40129564A (zh) 有效於治疗肝毒性及脂肪肝疾病的化合物及其用途
Luo et al. Retracted Article: Stereoisomers of octahydrocurcumin, the hydrogenated metabolites of curcumin, display stereoselective activity on the CYP2E1 enzyme in L-02 cells
CN103420805A (zh) 天麻中具有神经细胞保护活性的多聚苄类衍生物
EA040650B1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN114478464B (zh) 一种炎症小体选择性抑制剂及其合成方法和应用
Han et al. Synthesis and evaluation of scutellarein derivatives with improved neuroprotective activity and aqueous solubility
CN114539204A (zh) 血脑屏障高通透性己糖激酶抑制剂及其合成方法和应用